Breast Cancer Coverage from Every Angle
Advertisement
Advertisement

Sibylle Loibl, MD, on Clinical Challenges Associated With Use of Palbociclib and Endocrine Therapy for HR+ HER2– Breast Cancer

Posted: Tuesday, December 22, 2020

Sibylle Loibl, MD, of the German Breast Group, discusses phase III findings from the PENELOPE-B trial and the questions her research group intends to explore to improve overall adjuvant treatment for patients with hormone receptor–positive, HER2-negative breast cancer who are at high risk for relapse.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.